staff reporter
Articles Authored by staff reporter
Velsera to Integrate Arima Genomics Gene Fusion Test in Pierian Clinical Platform
Pierian, now a part of Velsera, is integrating Arima's gene fusion sequencing technology into its NGS analysis, interpretation, and reporting hub.
Abingdon Health to Distribute Salignostics' Pregnancy Test in UK, Ireland
Salignostics is based in Jerusalem and offers a number of saliva-based, lateral flow immunoassays.
FDA Updates 510(k) Clearances for Becton Dickinson, Roche, BioMérieux in January
The agency also cleared instruments and assays for blood gas and acid-base disturbances, antimicrobial susceptibility, and tacrolimus concentrations.
Centogene Regains Compliance with Nasdaq Listing Requirement
In December, the company was notified that its shares had failed to meet the Nasdaq's minimum bid price listing requirement.
Simple HealthKit Raises $8M in Series A Round
The California startup sells PCR-based tests for respiratory and sexually transmitted diseases and said it will use the funding toward innovation and expanded sales of its products.
LumiraDx Secures FDA Emergency Use Authorization, UK Approval for COVID-19, Flu Test
The LumiraDx SARS-CoV-2 & Flu A/B RNA STAR Complete test is a laboratory-use assay run on open RT-PCR instruments.
Rarity Bioscience Raises Additional €500,000
The Swedish molecular diagnostics startup raised the additional money as part of an oversubscription of an earlier €2.5 million seed financing round.
Top Five Articles on 360Dx Last Week: Roche Mass Spec Plans, Jana Care Collaboration; and More
Last week, readers were most interested in Roche's planned launch of its mass spec clinical analyzer in a market that has proven challenging for other vendors.
Genetic Technologies to Raise A$5M in Direct Stock Offering
The firm said several institutional investors had inked definitive agreements for the purchase and sale of 3,846,155 American Depositary Shares.
MDxHealth Prices $40M Public Offering
The diagnostics company is offering 10 million American Depositary Shares at $4.00 per share, with an option to underwriters to buy another 1.5 million.